Alok Ranjan, Ph.D.

Alok Ranjan, Ph.D.
Postdoctoral Fellow (CRTA)

Team Member of:

Dr. Ranjan is investigating the mechanistic roles of MBD3 and TMEM207, genes the lab has identified as being the regulators of the metastatic cascade through extensive in vivo screening. 

Areas of Expertise

1) metastasis, 2) molecular biology

Contact Info

Alok Ranjan, Ph.D.
Center for Cancer Research
National Cancer Institute
Bldg. 10-CRC; Rm. 3-5881
Bethesda, MD 20814
Ph: 240-858-3716

Dr. Ranjan’s current work involves investigation the mechanistic roles of MBD3 and TMEM207, genes the lab has identified as being the regulators of the metastatic cascade through extensive in vivo screening. MBD3 belongs to a family of nuclear protein that are characterized by the presence of methyl CpG binding domain (MBD). DNA methylation status is a major epigenetic modification that plays a significant role in acquisition of the metastatic phenotype. TMEM207 is a member of the transmembrane protein superfamily. Recently, TMEM207 expression has been shown to be deregulated in different cancers indicating its participation in tumorigenesis. Nonetheless, the precise pathophysiological role of TMEM207 remains largely unclear. Investigation will involve the employment of the molecular biology techniques as well as the use of multi-photon intravital microscopy to mechanistically investigate the dynamics of metastasis in the tissues. Findings will further be confirmed in several mouse models as well as in human tissues as a proof of concept.

Selected Publications

  1. Ranjan A, Gupta P, Srivastava SK.
    Cancer Res. 76(4): 877-890, 2016. [ Journal Article ]
  2. Ranjan A, Srivastava SK.
    Sci Reports. 6: 26165, 2016. [ Journal Article ]
  3. Ranjan A, Srivastava SK.
    Oncotarget. 8(20): 32960-32976, 2017. [ Journal Article ]
  4. Ranjan A, Wright S, Srivastava SK
    Oncotarget. 8(29): 47632-47641, 2017. [ Journal Article ]
  5. Ranjan A, German N, Mikelis C, Srivenugopal K, Srivastava SK
    Tumor Biol. 39(6): 1010428317705517, 2017. [ Journal Article ]

Dr. Ranjan received his Bachelor’s degree in Pharmaceutical Sciences from India in 2010, where he was ranked #1 for two consecutive years at Bachelor’s level. He started his doctoral research in the Department of Biomedical Sciences at Texas Tech University Health Sciences Center in the fall of 2012. During his graduate study, he served as Chair and Vice-President of American Association of Pharmaceutical Scientists students’ chapter of Texas Tech University, Amarillo. Dr. Ranjan’s doctoral research on cancer and metastasis earned him Scholar-In-Training Award at American Association for Cancer Research (AACR) and Graduate Student Research Award in Biotechnology at American Association of Pharmaceutical Scientists (AAPS). He defended his dissertation in December 2016 and was awarded with Outstanding Graduate Student of the Year award. After graduating, Dr. Ranjan joined the Thoracic and Gastrointestinal Oncology Branch at National Cancer Institute (NCI) as a postdoctoral fellow in the lab of Dr. Hernandez in March 2017.